- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05327647
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa)
A Phase II Randomized Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bladder cancer is the second most common urological cancer after prostate cancer. Non-muscle invasive bladder cancer (NIMBC) is the most common form (~ 75%). The standard treatment involves the use of intravesical instillation of bacillus Calmette-Guérin (BCG). Nonetheless, 30-40% of the patients still relapse or progress. Clinical and laboratory research suggests that medications targeting the androgen receptor, such as bicalutamide, combined with the standard treatment with BCG may decrease the recurrence rate of NMIBC.
The participants will be randomized to either the treatment with 1) daily intake of 150 mg bicalutamide for 3 months overlapping with the 6 cycles of intravesical instillations of BCG or 2) the standard of care of 6 cycles of intravesical instillation BCG . The participation to this this trial should last 36 months from the screening visit to the last follow-up visit.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Paul Toren, MD,PhD,FRCSC
- Phone Number: 17064 418-525-4444
- Email: paul.toren@crchudequebec.ulaval.ca
Study Locations
-
-
-
Québec, Canada, G1G 5X1
- Recruiting
- CHU de Quebec-Universite Laval
-
Contact:
- Paul Toren, MD
- Phone Number: 17064 418-525-4444
- Email: Paul.toren@crchudequebec.ulaval.ca
-
Contact:
- Typhaine Gris, PhD
- Phone Number: 20417 418 525-4444
- Email: typhaine.gris@crchudequebec.ulaval.ca
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- London Health Sciences Centre
-
Contact:
- Melissa Huynh, MD
- Phone Number: 519-685-8451
- Email: Melissa.Huynh@LHSC.on.ca
-
-
Quebec
-
Montréal, Quebec, Canada, H2X 3E4
- Recruiting
- Centre Hospitalier de l'Université De Montréal_CHUM
-
Contact:
- Jean-Baptiste Lattouf, MD
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Centre_CUSM
-
Contact:
- Wassim Kassouf, MDCM
- Phone Number: (514) 934-8246
- Email: wassim.kassouf.med@ssss.gouv.qc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males, age 18 or greater.
- Patients with histologically confirmed non-muscle invasive urothelial carcinoma.
- Patients have been recommended for a course of intravesical BCG induction treatment by their urologist
- Patients who received gemcitabine, epirubicin or mitomycin C instillations immediately post-operatively will be eligible for enrollment.
- Patients with partners of child-bearing potential must agree to 2 acceptable forms of birth control and be continued for at least 3 months after study drug is discontinued.
Exclusion Criteria:
- Patients who have received induction BCG therapy within the last 5 years will be ineligible for enrollment.
- Patients who have received an induction course of intravesical chemotherapy within the last 5 years will be ineligible for enrollment.
- Patients with a history of myocardial infarction or hospital admission for heart failure within the previous 12 months or who have unstable cardiovascular status will be ineligible for enrollment.
- Patients who have uncontrolled hypertension (for our purposes, defined as those having a systolic blood pressure > 160 documented on 2 occasions despite appropriate medical therapy) will similarly be ineligible.
- Patients with a history of venous thrombo-embolism (DVT/PE) within the past 3 years.
- Patients with a history of liver disease whose hepatic enzymes, alkaline phosphatase or bilirubin are greater than twice the upper limit of normal will be ineligible.
- Patients with kidney disease with an estimated glomerular filtration rate (eGFR) < 30 will be ineligible.
- Patients with neutropenia (< 3,000/μL) will be ineligible.
- Patients with clinical hypogonadism, those on androgen replacement therapy, or those with prostate cancer or other diseases treated with various forms of hormonal therapy will be ineligible for study enrollment. Patients receiving 5-alpha-reductase inhibitors will not be excluded.
- Patients who have undergone treatment for any malignancy other than bladder cancer within the past 2 years except for superficial non-melanoma skin cancers.
- Patients with prior history of prostate cancer treated by definitive local therapy > 5 years ago will only be eligible if they have had no clinical or biochemical evidence of recurrent prostate cancer.
- Patients taking an investigational drug within 3 weeks of enrollment into this study.
- Patients receiving or planning to receive coumadin therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bicalutamide
Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral bicalutamide for 90 days
|
Induction intravesical BCG with bicalutamide 150 mg for 90 days
Other Names:
|
Active Comparator: Control Arm
Induction intravesical Bacille Calmette-Guérin treatment
|
Induction BCG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of bladder tumour recurrence
Time Frame: 3 years
|
To time to bladder tumor recurrence compared to the standard of care induction BCG
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of tumour progression
Time Frame: 3 years
|
To compare the incidence of tumor progression between the intervention and control arms
|
3 years
|
Number of tumor recurrences
Time Frame: 3 years
|
To compare the overall incidence of tumor recurrences between intervention and control arms
|
3 years
|
Number of tumours at first recurrence
Time Frame: 3 years
|
Evaluation of the number of tumours at first recurrence between the two arms
|
3 years
|
Quality of life (QLQ-C30)
Time Frame: 3 years
|
Evaluation of quality of life with QLQ-C30 questionnaire (EORTC Core Quality of Life questionnaire).
The scale scores range from 0 to 100.
A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom
|
3 years
|
Evaluation of urinary symptoms
Time Frame: 3 years
|
Evaluation of urinary symptoms with International Prostate Symptom Score (IPSS) .
questionnaire.
The total score can range from 0 to 35 (0 being asymptomatic and 35 being very symptomatic).
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Paul Toren, MD,PhD,FRCSC, CHU de Quebec-Universite Laval
- Principal Investigator: Wassim Kassouf, MDCM,FRCSC, McGill University Health Centre/Research Institute of the McGill University Health Centre
- Principal Investigator: Melissa Huynh, MD,MPH,FRCSC, London Health Sciences Centre, Victoria Hospital
- Principal Investigator: Jean-Baptiste Lattouf, MD,FRCSC, Centre Hospitalier Universitaire de Montréal (CHUM)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Bicalutamide
- Androgen Antagonists
- Nonsteroidal Anti-Androgens
Other Study ID Numbers
- MP-20-2022-6318
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Muscle Invasive Bladder Cancer
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Huazhong University of Science and TechnologyRecruitingBladder Cancer | Non-Muscle-Invasive Bladder CancerChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
-
RenJi HospitalBeiGene; RemeGen Co., Ltd.RecruitingHER2 | Non-Muscle Invasive Bladder CancerChina
-
White River Junction Veterans Affairs Medical CenterMedical University of South Carolina; National Cancer Institute (NCI); University...RecruitingNon-muscle-invasive Bladder CancerUnited States
-
Al-Azhar UniversityRecruiting
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Recruiting
Clinical Trials on Bicalutamide
-
University of Wisconsin, MadisonPfizerTerminatedProstate CancerUnited States
-
Fox Chase Cancer CenterCompletedCancer of ProstateUnited States
-
AstraZenecaNo longer availableAdenocarcinoma of the Prostate
-
University of L'AquilaCompletedProstate CancerItaly
-
Alessa Therapeutics Inc.CompletedLower Urinary Tract Symptoms | Prostate AdenocarcinomaUnited States, Australia, New Zealand
-
SandozCompleted
-
Royal College of Surgeons, IrelandUniversity College Dublin; University of Oxford; University of Liverpool; University...Not yet recruitingPolycystic Ovary Syndrome | Metabolic Disease | Androgen ExcessIreland
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Withdrawn
-
Astellas Pharma IncMedivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstatic NeoplasmsUnited States, Belgium, Canada, Denmark, France, Germany, Romania, United Kingdom
-
SandozCompleted